Stryker Corporation $SYK Shares Bought by Swedbank AB

Key Points

• Swedbank AB increased its holdings in Stryker Corporation by 0.9%, owning 113,236 shares valued at approximately $42.15 million as of the latest filing with the SEC.
• Insider transactions include Director Ronda E. Stryker selling 200,000 shares for about $75.29 million, resulting in a 5.84% reduction in her stake.
• Research firms are optimistic about Stryker, with target prices set by various analysts ranging from $415 to $448, reflecting a consensus average target price of $431.42.

Swedbank AB grew its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 0.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,236 shares of the medical technology company's stock after purchasing an additional 995 shares during the period. Swedbank AB's holdings in Stryker were worth $42,152,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of SYK. Capital A Wealth Management LLC acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker in the 1st quarter valued at $32,000. City Holding Co. lifted its stake in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Ransom Advisory Ltd acquired a new position in shares of Stryker in the 1st quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research reports. Truist Financial set a $415.00 target price on Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Needham & Company LLC increased their target price on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. BTIG Research reissued a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Finally, Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $431.42.

Stryker Price Performance

Shares of NYSE SYK opened at $383.32 on Friday. The stock's 50-day moving average is $388.98 and its two-hundred day moving average is $379.57. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $146.55 billion, a price-to-earnings ratio of 50.77, a price-to-earnings-growth ratio of 2.80 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the business posted $2.81 EPS. The business's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.